Recent Company News

• 07:14 PM ET Aug 11, 2026
  

  Clinuvel Pharmaceuticals advancing controlled-release injectable liquid peptide platform VLRX-L (A$9.71, 0.00)

• 06:59 PM ET Jul 27, 2026
  

  Clinuvel Pharmaceuticals provides updates on SCENESSE in vitiligo; SCENESSE and adjuvant narrowband UVB to be evaluated (A$9.81, 0.00)

• 07:15 PM ET Jul 22, 2026
  

  Clinuvel Pharmaceuticals to pivot operational resources exclusively toward the US pharmaceutical pipeline and commercial strategy (A$9.88, 0.00)

• 09:33 PM ET Jun 17, 2026
  

  StreetAccount Summary - Trading higher/lower: Australia & New Zealand midday

• 06:36 PM ET Jul 12, 2026
  

  Clinuvel Pharmaceutical's SCENESSE granted Notice of Compliance by Health Canada (A$10.27, 0.00)

• 07:11 PM ET Jun 15, 2026
  

  Clinuvel Pharmaceuticals files to upgrade its ADR program from Level I to Level II and trade on Nasdaq (A$9.25, 0.00)

• 01:00 AM ET Jun 11, 2026
  

  StreetAccount Summary: Australia and New Zealand Stocks reaching new 52-week highs/lows (65 total)